AstraZeneca PLC Ordinary Shares (AZN)
Stock · NYSE · Health Care
$162.7as of 8/28/2026
Price chart
Open in TradingViewActive signals
Support Reject35.0%
High Beta23.0%
Resistance level
$182.19
Industry
Biotechnology: Pharmaceutical Preparations
About AZN
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil,…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 96,100
- Website
- www.astrazeneca.com/
Fundamentals
- 1-day range
- $161.18$163.54
- Market cap
- $244.97B
- P/E (trailing)
- 23.44
- P/E (forward)
- 14.32
- EPS (trailing)
- $6.69
- Dividend yield
- 2.30%
- Beta
- 1.38
- Avg. volume
- 3.08M
- Ex-dividend date
- August 7, 2026
- Dividend pay date
- September 8, 2026
52-week range
$10,784$15,730
Next earnings: October 30, 2026 · EPS estimate $1.30confirmed
Forecasts
11 analyst ratings
Buy 83%
Hold 14%
Sell 3%
1-year price forecast
High
$240
+47.5%
Median
$215
+32.1%
Low
$184
+13.1%
AstraZeneca PLC Ordinary Shares Competitors
Chosen by industry and closest market cap.
- AZNAstraZeneca PLC Ordinary Shares$162.69▼ 1.11%Market cap $244.97BP/E 23.44$10,784$15,730
- NVONovo Nordisk A/S Common Stock$45.6▼ 1.43%Market cap $208.51BP/E 11.40$224.25$409.95
- NVSNovartis AG Common Stock$153.79▼ 0.56%Market cap $293.23BP/E 21.95$96.03$131.5
- ABTAbbott Laboratories Common Stock$112.42▲ 0.74%Market cap $185.36BP/E 35.52$81.97$137.49
- MRKMerck & Company Inc. Common Stock (new)$148.32▼ 0.82%Market cap $315.57BP/E 103.86$77.58$156.92
- PFEPfizer Inc. Common Stock$27.95▼ 0.25%Market cap $142.66BP/E 35.19$23.58$28.75
- VRTXVertex Pharmaceuticals Incorporated Common Stock$541.72▼ 1.06%Market cap $119.47BP/E 30.70$374.17$555.69
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| AZN AstraZeneca PLC Ordinary Shares | $244.97B | 23.44 | $162.69 | ▼ 1.11% | $10,784$15,730 |
| NVO Novo Nordisk A/S Common Stock | $208.51B | 11.40 | $45.6 | ▼ 1.43% | $224.25$409.95 |
| NVS Novartis AG Common Stock | $293.23B | 21.95 | $153.79 | ▼ 0.56% | $96.03$131.5 |
| ABT Abbott Laboratories Common Stock | $185.36B | 35.52 | $112.42 | ▲ 0.74% | $81.97$137.49 |
| MRK Merck & Company Inc. Common Stock (new) | $315.57B | 103.86 | $148.32 | ▼ 0.82% | $77.58$156.92 |
| PFE Pfizer Inc. Common Stock | $142.66B | 35.19 | $27.95 | ▼ 0.25% | $23.58$28.75 |
| VRTX Vertex Pharmaceuticals Incorporated Common Stock | $119.47B | 30.70 | $541.72 | ▼ 1.06% | $374.17$555.69 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- AstraZeneca, Amgen Score Phase 3 Win in Debilitating Swallowing Diseasebenzinga · 8/27/2026
- AstraZeneca, Amgen Score Phase 3 Win in Debilitating Swallowing DiseaseBenzinga · 8/27/2026
- AstraZeneca, Amgen Report Phase III Results For TEZSPIRE In Eosinophilic Esophagitis; TEZSPIRE Meets Key Endpoints In Phase III CROSSING TrialBenzinga · 8/27/2026
- Amgen And AstraZeneca's TEZSPIRE Meets Both Co-Primary And All Key Secondary Endpoints In Phase 3 CROSSING Trial For Eosinophilic EsophagitisBenzinga · 8/27/2026
- AstraZeneca And Daiichi Sankyo Dose First Patient In Phase 3 TROPION-Urothelial04 Trial Of Datroway In Muscle-Invasive Urothelial CancerBenzinga · 8/26/2026
- Tempus AI Just Had Their Entire Strategy Validated By Moderna's Vaccine AdvanceSeekingAlpha · 8/20/2026
- Silence Therapeutics: Making Some Recent NoiseSeekingAlpha · 8/19/2026
- AstraZeneca Vs. Bristol-Myers Squibb: Who's The Better Bargain For Investors?SeekingAlpha · 8/19/2026
- BioMarin Seeks to Strengthen Market Position in Rare Bone Disease TreatmentBenzinga · 8/18/2026
Insider Activity
Insider Actions →Acquired
5
Disposed
11.9K
- Sharma Mani · August 6, 2026 · Grant2 @ $163.34
- Sharma Mani · July 6, 2026 · Grant2 @ $190.43
- Sharma Mani · June 8, 2026 · Grant1 @ $179.75
- Sharma Mani · May 20, 2026 · Sale11.9K @ $185.78
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedSynthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
August 30, 2026
AZN: Tezspire Phase 3 Win in Eosinophilic Esophagitis, New Datroway Trial. AstraZeneca and partner Amgen reported that their drug Tezspire met both co-primary and all key secondary endpoints in the Phase 3 CROSSING trial for eosinophilic esophagitis, a chronic swallowing disorder. Positive Phase 3 results can support future regulatory filings and broaden the drug's addressable market. Separately, AstraZeneca and Daiichi Sankyo dosed the first patient in the Phase 3 TROPION-Urothelial04 trial of Datroway in muscle-invasive urothelial cancer, expanding the pipeline for that antibody-drug conjugate. Analysts currently track an average price target of $213.69 with a $184.00 floor, while the shares trade near a well-tested support level around $182.19.